Ability of Aridol to Detect Bronchial Hyperresponsiveness in Suspected Asthmatics

Inclusion criteria

• Have given informed consent to participate in this study in accordance with local regulations prior to any procedures being performed
• Have signs and symptoms suggestive of asthma according to the NIH Questionnaire but has not been given a firm diagnosis of asthma or a firm exclusion of the diagnosis of asthma (e.g. has an equivocal diagnosis of asthma or been referred for further investigation of asthma type symptoms)
• Have at least Step 1 symptoms according to the NAEPPII asthma severity grading
• Have an FEV1 ≥ 70% of the predicted value at Screening Visit (Visit 1) baseline
• Be between 6 and 50 years
• Be able to perform all of the techniques necessary to measure lung function including an exercise challenge, Aridol challenge and methacholine challenge
• Be able to understand the requirements of the study and be able to complete all of the forms necessary including the NIH Questionnaire
• Be taking effective birth control if female of childbearing potential

Exclusion criteria

• Use medications six weeks prior to the Screening Visit (Visit 1) or during the study that would interfere with bronchial provocation challenge testing (see Table 1, section 3.3.3.4)
• Currently use cholinesterase-inhibitor medication (for myasthenia gravis)
• Have had upper or lower respiratory tract infection within the previous 4 weeks
• Have known aortic or cerebral aneurysm, cirrhosis or portal hypertension
• Have had recent major surgery
• Have had recent cataract surgery
• Have a history of heart disease that would increase risk of performing exercise, methacholine or Aridol challenge
• Have had cardiac ischemia or malignant arrhythmias
• Have uncontrolled hypertension (systolic blood pressure ≥ 180 and diastolic blood pressure ≥ 100)
• Have orthopedic limitations
• Have smoked within the past year (average > 1 cigarette per week), or have a ≥ 10 pack year smoking history
• Have other chronic restrictive or obstructive pulmonary diseases (cystic fibrosis, COPD, bronchiectasis, chronic bronchitis, emphysema, tuberculosis, pulmonary carcinoma, pulmonary fibrosis, pulmonary hypertension, hypercapnia)
• Be skin test positive to seasonal and perennial aeroallergens that are present in the environment during the time that the subject is enrolled in the study, or if skin test positive to these aeroallergens the subject must not report worsening of symptoms when exposed to these aeroallergens during the time that the subject is participating in the study
• Have a medical condition that in the opinion of the Investigator would impair the ability of the subject to participate
• Have an inability to perform spirometry of acceptable quality
• Be intolerant to Aridol, methacholine or albuterol
• Be pregnant or lactating
• Have participated in any other investigative drug study parallel to, or within 4 weeks of study entry
• Be an Investigator, site employee or otherwise be directly affiliated with the study site including being a member of the immediate family of an Investigator, site employee (where an immediate family member is defined as spouse, parent, child or sibling, whether biological or legally adopted or in foster care)
• Have a body mass index (BMI) ≥ 30
• Have been diagnosed at Screening Visit (Visit 1) as definitively having or not having asthma; patients that will not continue in the study include those given the following diagnosis: asthma is extremely likely or definite (95 to 100% likelihood) or asthma is very unlikely or excluded (0 to < 5% likelihood)
• Have previously been enrolled in this study at this or at any other clinical trials site
• Have previously received an Aridol challenge
• Have a clinically significantly abnormal chest x-ray